Trial Profile
Open, Prospective, Single-center Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato 500) in the Treatment of Basal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- Acronyms PICABAS
- 20 Jul 2023 Status changed from recruiting to completed.
- 26 Jun 2020 Status changed from not yet recruiting to recruiting.
- 11 Jun 2018 New trial record